Expedia vs Galaxy Surfactants

Expedia and Galaxy Surfactants are two well-known companies in the stock market, with Expedia being a major player in the online travel industry and Galaxy Surfactants specializing in specialty chemicals. Both companies have seen fluctuations in their stock prices in recent months, with Expedia facing challenges due to the impact of the COVID-19 pandemic on the travel industry, while Galaxy Surfactants has been affected by changes in the global economy. Investors are closely monitoring the performance of these stocks to make informed decisions on their investment portfolios.

Expedia

Galaxy Surfactants

Stock Price
Day Low$150.29
Day High$152.57
Year Low$92.48
Year High$160.05
Yearly Change73.06%
Revenue
Revenue Per Share$100.52
5 Year Revenue Growth0.18%
10 Year Revenue Growth1.50%
Profit
Gross Profit Margin0.40%
Operating Profit Margin0.08%
Net Profit Margin0.06%
Stock Price
Day Low₹2910.00
Day High₹3139.00
Year Low₹2247.00
Year High₹3370.00
Yearly Change49.98%
Revenue
Revenue Per Share₹1079.31
5 Year Revenue Growth0.39%
10 Year Revenue Growth1.24%
Profit
Gross Profit Margin0.27%
Operating Profit Margin0.10%
Net Profit Margin0.08%

Expedia

Galaxy Surfactants

Financial Ratios
P/E ratio24.69
PEG ratio-1.14
P/B ratio22.44
ROE64.82%
Payout ratio0.00%
Current ratio0.76
Quick ratio0.76
Cash ratio0.47
Dividend
Dividend Yield-%
5 Year Dividend Yield0.00%
10 Year Dividend Yield0.00%
Expedia Dividend History
Financial Ratios
P/E ratio36.07
PEG ratio0.44
P/B ratio5.06
ROE14.54%
Payout ratio0.00%
Current ratio0.00
Quick ratio0.00
Cash ratio0.00
Dividend
Dividend Yield0.71%
5 Year Dividend Yield25.74%
10 Year Dividend Yield0.00%
Galaxy Surfactants Dividend History

Expedia or Galaxy Surfactants?

When comparing Expedia and Galaxy Surfactants, different investors may prioritize various metrics based on their investment strategies and goals. So, ask yourself what type of investor you are. This will guide you in determining which metrics are most important for your investment decision between Expedia and Galaxy Surfactants.

Dividend Investors:

Dividend investors look for stable and growing income streams, using dividend metrics to assess potential investments. A company's dividend yield essentially measures the size of its dividend relative to the total market value of the company. Expedia has a dividend yield of -%, while Galaxy Surfactants has a dividend yield of 0.71%. Beyond the yield itself, considering the growth and sustainability of these dividends is also crucial. Expedia reports a 5-year dividend growth of 0.00% year and a payout ratio of 0.00%. On the other hand, Galaxy Surfactants reports a 5-year dividend growth of 25.74% year and a payout ratio of 0.00%.

Value Investors:

Value investors focus on financial metrics to determine a stock's intrinsic value compared to its market value. The Price-to-Earnings (P/E) Ratio links stock price to a company's earnings per share, with Expedia P/E ratio at 24.69 and Galaxy Surfactants's P/E ratio at 36.07. Another crucial valuation metric is the Price-to-Book (P/B) Ratio, which compares stock price with book value per share. Expedia P/B ratio is 22.44 while Galaxy Surfactants's P/B ratio is 5.06.

Growth Investors:

Growth investors prioritize metrics indicative of a company's expansion potential. Focusing on top-line growth, Expedia has seen a 5-year revenue growth of 0.18%, while Galaxy Surfactants's is 0.39%. Return on Equity (ROE) measures how effectively a company uses equity investment to generate earnings, with Expedia's ROE at 64.82% and Galaxy Surfactants's ROE at 14.54%.

Retail Investors:

Retail investors often consider stock affordability and company familiarity. For example, day low prices are $150.29 for Expedia and ₹2910.00 for Galaxy Surfactants. Over the past year, Expedia's prices ranged from $92.48 to $160.05, with a yearly change of 73.06%. Galaxy Surfactants's prices fluctuated between ₹2247.00 and ₹3370.00, with a yearly change of 49.98%. Brand recognition also plays a role, as familiarity with a company can influence investment decisions.

Comparision